About axatilimab csfr
CSF-1 receptor-blocking monoclonal antibody
Used for
- Treats chronic graft-versus-host disease after failure of at least two prior systemic treatments.
Usual adult dose
Adults and children aged 6 years or older: 0.3 mg/kg intravenously every two weeks; maximum 35 mg per dose.
Usual dose in children
For ages 6 years and older: 0.3 mg/kg intravenously every two weeks; maximum 35 mg per dose.
Common side effects
- Infections
- Increased liver enzymes
- Anemia
- Swelling or fluid retention
Important warnings
- Can cause serious infections; assess and monitor during treatment.
- May cause liver injury; check liver tests before and during treatment.
- Can cause infusion reactions; monitor during and after infusions.
- May interfere with laboratory tests measuring certain immune-related markers.
Pregnancy
There are no adequate human pregnancy data. Animal findings suggest possible fetal harm; effective contraception is advised during treatment and for two months afterward.
Breastfeeding
It is unknown whether axatilimab passes into breast milk. Weigh breastfeeding benefits against treatment needs and potential infant effects.
Interactions
- No formal interaction studies have been conducted; clinically significant interactions are not established.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.